Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_assertion type Assertion NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_head.
- NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_assertion description "[Using rocket immunoelectrophoresis, ELISA, and Luminex xMAP technology, we analyzed plasma levels of alpha(1)-antichymotrypsin and alpha(1)-antitrypsin, and CSF levels of alpha(1)-antichymotrypsin, alpha(1)-antitrypsin, and neuroserpin along with three standard biomarkers (total tau, tau phosphorylated at threonine-181, and the A beta(1-42)) in patients with AD (n = 258), patients with dementia with Lewy bodies (DLB; n = 38), and age-matched controls (n = 37).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_provenance.
- NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_assertion evidence source_evidence_literature NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_provenance.
- NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_assertion SIO_000772 17761554 NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_provenance.
- NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_assertion wasDerivedFrom befree-20150227 NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_provenance.
- NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_assertion wasGeneratedBy ECO_0000203 NP217935.RAlVHhRicnNTEYMWGi099iMKMC2K4LjPvH78RL26WZFXk130_provenance.